臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"hsu c h"的相关文件

回到依作者浏览
依题名排序	依日期排序

显示项目 291-315 / 1656 (共67页)
<< < 7 8 9 10 11 12 13 14 15 16 > >>
每页显示[10|25|50]项目

机构	日期	题名	作者
臺大學術典藏	2021-09-01T01:53:55Z	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems	Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:53:53Z	The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma	Shao Y.-Y.; Chang Y.-L.; Huang C.-Y.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:53:49Z	Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma	Lu L.-C.; Shao Y.-Y.; Kuo R.N.C.; Lin Z.-Z.; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; ANN-LII CHENG; Lai M.-S.
臺大學術典藏	2021-09-01T01:53:47Z	Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study	Hsu C.-H.; Kang Y.K.; Yang T.-S.; Shun C.-T.; Shao Y.-Y.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Hsu C.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:53:46Z	Nuclear expression of glioma-associated oncogene homolog 1 and nuclear factor-κb is associated with a poor prognosis of pancreatic cancer	Yang S.-H.; Hsu C.-H.; Lee J.-C.; Tien Y.-W.; Kuo S.-H.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:53:45Z	A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy	Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; ANN-LII CHENG; Lin Z.-Z.
臺大學術典藏	2021-09-01T01:53:45Z	Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy	Chen W.-W.; Lin C.-C.; Huang T.-C.; ANN-LII CHENG; Yeh K.-H.; Hsu C.-H.
臺大學術典藏	2021-09-01T01:53:44Z	Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study	Johnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; Hsu C.-H.; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Avi?a J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:53:43Z	Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size	Lin Z.-Z.; Shau W.-Y.; Hsu C.; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; ANN-LII CHENG; Lai M.-S.
臺大學術典藏	2021-09-01T01:53:42Z	Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy	Lu L.-C.; Shao Y.-Y.; Chan S.-Y.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:42:28Z	�]-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma	Lu L.-C.; Shao Y.-Y.; Lee Y.-H.; Hsieh M.-S.; Hsiao C.-H.; Lin H.-H.; Kao H.-F.; Ma Y.-Y.; Yen F.-C.; ANN-LII CHENG; Hsu C.-H.
臺大學術典藏	2021-08-31T06:42:27Z	Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases	Shao Y.-Y.; Ho M.-C.; ANN-LII CHENG; Hsu C.-H.
臺大學術典藏	2021-08-31T06:42:23Z	Clinical activity of metronomic chemotherapy in liver cancers	Shao Y.-Y.; ANN-LII CHENG; Hsu C.-H.
臺大學術典藏	2021-08-31T06:42:23Z	Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy	Shao Y.-Y.; Wu C.-H.; Lu L.-C.; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:42:22Z	A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies	Lin C.-C.; Su W.-C.; Yen C.-J.; Hsu C.-H.; Su W.-P.; Yeh K.-H.; Lu Y.-S.; ANN-LII CHENG; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H.
臺大學術典藏	2021-08-31T06:42:19Z	Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials	Shao Y.-Y.; Shau W.-Y.; Chan S.-Y.; Lu L.-C.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:49Z	Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?	Shao Y.-Y.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:49Z	Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan	Shao Y.-Y.; Hsu C.-H.; Yeh K.-H.; Chen H.-M.; Yeh Y.-C.; Lai C.-L.; Lin Z.-Z.; ANN-LII CHENG; Lai M.-S.
臺大學術典藏	2021-08-31T06:29:49Z	High serum transforming growth factor-�]1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenib	Lin T.-H.; Shao Y.-Y.; Chan S.-Y.; Huang C.-Y.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:48Z	Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma	Guo J.-C.; Huang T.-C.; Lin C.-C.; Hsieh M.-S.; Chang C.-H.; Huang P.-M.; Lee J.-M.; Hsu F.-M.; Cheng J.C.-H.; Wang H.-P.; Yeh K.-H.; ANN-LII CHENG; Hsu C.-H.
臺大學術典藏	2021-08-31T06:29:46Z	Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy	Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; ANN-LII CHENG; Shih T.T.-F.
臺大學術典藏	2021-08-31T06:29:44Z	Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges	Lu L.-C.; Hsu C.-H.; Hsu C.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:43Z	Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma	Shao Y.-Y.; Liu T.-H.; Lee Y.-H.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:42Z	Inhibition of the Wnt/�]-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma	Lin H.-H.; Feng W.-C.; Lu L.-C.; Shao Y.-Y.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:42Z	Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer	Yang S.-H.; Kuo T.-C.; Wu H.; Guo J.-C.; Hsu C.; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; ANN-LII CHENG; Kuo S.-H.

显示项目 291-315 / 1656 (共67页)
<< < 7 8 9 10 11 12 13 14 15 16 > >>
每页显示[10|25|50]项目

	English \| 正體中文 \| 简体中文 \| 总笔数 :2828323
	造访人次 : 32242951 在线人数 : 2082 教育部委托研究计画计画执行:国立台湾大学图书馆